• Age: 18 years or above, gender not restricted;

• Patients who meet the diagnostic criteria for chemotherapy-related thrombocytopenia, and still ineffective after repeated treatment with rhTPO or IL-11 (subjects need to undergo regular rhTPO treatment for at least 14 days after radiotherapy and chemotherapy, with a dose of rhTPO 300u/kg/d or higher, and the platelet count remains less than 30×10\^9/L, defined as refractory CTIT);

• Patients who have stopped chemotherapy and radiotherapy for more than 1 month;

• Patients with platelet count at enrollment \< 30×10\^9/L;

• Patients with platelet count remains \< 30×10\^9/L for more than 1 month;

• Patients with expected survival period ≥ 6 months;

• Patients with liver and kidney function \< 1.5× upper limit of normal value, physical examination qualified;

• Patients with ECOG physical status score ≤ 2 points;

• Patients with Cardiac function: New York Heart Association cardiac function classification is grade 2 or below;

• Patients who is voluntary to sign the informed consent form;